Delaware biologics regulations.

Who may administer PRP, exosomes and stem cells in Delaware, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Delaware?

In Delaware, licensed physicians, osteopathic physicians, and other advanced-level medical professionals are typically eligible to administer biologics and stem cell therapies. Licensed MD/DO can administer but PAs and NPs require supervising physician’s approval to administer treatment.

Official sources

Delaware compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) regulates biologic products, including human cell and tissue-based products (HCT/Ps). Under FDA’s guidelines for HCT/P, products must meet specific requirements, especially if they involve stem cell treatments. Clinics are advised to familiarize themselves with 21 CFR Part 1271, which addresses registration, donor eligibility, and manufacturing practices.

Delaware State Regulations

Delaware’s state regulations on biologics can be accessed through the Delaware Division of Public Health. The state’s regulations align with federal guidelines, requiring providers to follow FDA standards in HCT/P offerings. Understanding Delaware’s guidelines is crucial for accessible and confident compliance.

Provider Qualifications

In Delaware, licensed physicians, osteopathic physicians, and other advanced-level medical professionals are typically eligible to administer biologics and stem cell therapies. Licensed MD/DO can administer but PAs and NPs require supervising physician’s approval to administer treatment. To verify licensure requirements, consult the Delaware Division of Professional Regulation. Qualified providers are encouraged to ensure proper training and credentialing to confidently meet compliance requirements.

Patient Informed Consent

Obtaining informed consent is essential. Delaware requires that patients understand the risks, benefits, and the experimental nature of certain biologic treatments. Consent forms should clearly outline any potential adverse effects, the unproven nature of certain therapies, and include any disclaimers necessary to ensure patients’ informed participation.

Pre-Treatment and Post-Treatment Protocols

Standardized protocols are recommended for pre-treatment and post-treatment processes. Clinics should establish SOPs that ensure patient safety, appropriate handling of biologic materials, and thorough documentation.

Medical Liability Insurance

Biologics providers in Delaware should carry adequate medical liability insurance that covers the unique risks associated with stem cell therapies. Contact insurance providers to ensure comprehensive coverage that meets the specific requirements of biologic treatments.

Marketing Compliance

Delaware clinics must follow ethical marketing guidelines. Avoid unverified claims about treatment outcomes and always adhere to both FDA and Delaware regulations regarding biologic therapy advertising.

This guide is a general summary to help clinics understand compliance requirements for biologics in Delaware. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Delaware: common questions.

Who can administer stem cells, PRP and exosomes in Delaware?
In Delaware, licensed physicians, osteopathic physicians, and other advanced-level medical professionals are typically eligible to administer biologics and stem cell therapies. Licensed MD/DO can administer but PAs and NPs require supervising physician’s approval to administer treatment. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Delaware?
FDA rules are federal, so they apply in Delaware as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Delaware?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Delaware?
Start with the live webinar, then a discovery call and live training. After that we verify your Delaware licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Delaware? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.